Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P13 vs Remicade in Active Crohn's Disease
NCT02096861Phase 3Completed
- Sponsor
- Celltrion
- Start
- Sep 2014
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of infliximab-dyyb in Crohn's disease (4 arms), sponsored by Celltrion. Primary endpoint: Clinical Response According to Crohn's Disease Activity Index (CDAI)-70 Criteria at Week 6. Started Sep 2014; status: completed.
02
Drugs
infliximab-dyyb
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02096861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02096861.